Cargando…
The CD4+/CD14+HLA-DRlo/neg ratio as a prognostic biomarker in cancer patients
Autores principales: | Dietz, Allan B, Gustafson, Michael P, Lin, Yi, LaPlant, Betsy, Liwski, Courtney J, Maas, Mary L, League, Stacy C, Bauer, Philippe R, Abraham, Roshini S, Tollefson, Matthew K, Kwon, Eugene D, Gastineau, Dennis A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990349/ http://dx.doi.org/10.1186/2051-1426-1-S1-P50 |
Ejemplares similares
-
Immune monitoring using the predictive power of immune profiles
por: Gustafson, Michael P, et al.
Publicado: (2013) -
Expression profiling of suppressive monocytes (CD14+HLA-DRlow/neg) in cancer patients
por: Cordes, Stefan F, et al.
Publicado: (2013) -
The CD14(+)HLA-DR(lo/neg) Monocyte: An Immunosuppressive Phenotype That Restrains Responses to Cancer Immunotherapy
por: Mengos, April E., et al.
Publicado: (2019) -
Immune independent crosstalk between lymphoma and myeloid suppressor CD14(+)HLA-DR(low/neg) monocytes mediates chemotherapy resistance
por: Zhang, Zhe (Jenny), et al.
Publicado: (2015) -
Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14(+)HLA-DR(lo/neg) Cells): The Gateway to Improved Responses
por: Laborde, Rebecca R., et al.
Publicado: (2014)